Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Nonalcoholic Steatohepatitis (NASH): Update Bulletin [February 2018]

Product Code:
596200946
Publication Date:
February 2018
Format:
PDF
Price:
£1,140

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals announcing the initiation of the global Phase III REVERSE study to evaluate the efficacy and safety of obeticholic acid (OCA; Ocaliva); Madrigal Pharmaceuticals reports positive top-line data from a Phase II clinical trial assessing MGL-3196 and GENFIT announcing the launch of the first clinical study in paediatric NASH patients to evaluate safety and efficacy of its dual PPARα/δ agonist elafibranor. 

Business Questions:

  • What are KOL’s current views on obeticholic acid (OCA; Ocaliva) and what would they like to see from longer-term data?
  • How do KOLs view the studies in the cirrhotic NASH patients given safety concerns with Ocaliva in PBC setting?
  • Do KOLs think OCA can meet its primary endpoint in the REVERSE study?
  • How do KOLs think OCA, if approved for NASH, is likely to be priced?
  • How do KOLs rate the potential of Madrigal’s MGL-3196?
  • Where is MGL-3196 best likely to fit into the treatment strategy? What do KOLs say?
  • How do KOLs arte the development of elafibranor in paediatric NASH?
  • What concerns do experts have with elafibranor in children?
  • What are KOLs expecting from the Phase III RESOLVE-IT study for elafibranor?



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved